Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Johnson and Johnson
Mallinckrodt
Merck
Medtronic

Last Updated: March 26, 2023

Ucb Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Ucb Inc
International Patents:298
US Patents:15
Tradenames:27
Ingredients:22
NDAs:40
Drug Master File Entries: 1

Drugs and US Patents for Ucb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-001 May 9, 2007 RX Yes Yes 10,350,174 See Plans and Pricing Y See Plans and Pricing
Ucb Inc AMITRIPTYLINE HYDROCHLORIDE amitriptyline hydrochloride TABLET;ORAL 086335-001 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Ucb Inc AMITRIPTYLINE HYDROCHLORIDE amitriptyline hydrochloride TABLET;ORAL 085935-001 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-001 May 12, 2016 AB RX Yes No See Plans and Pricing See Plans and Pricing
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-006 Apr 2, 2012 RX Yes No 10,130,589 See Plans and Pricing Y See Plans and Pricing
Ucb Inc PARCOPA carbidopa; levodopa TABLET, ORALLY DISINTEGRATING;ORAL 076699-003 Aug 27, 2004 DISCN No No See Plans and Pricing See Plans and Pricing
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-003 May 12, 2016 AB RX Yes No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Ucb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-001 Oct 28, 2008 5,654,301 See Plans and Pricing
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-002 May 12, 2016 8,492,416 See Plans and Pricing
Ucb Inc VIMPAT lacosamide SOLUTION;ORAL 022255-001 Apr 20, 2010 5,654,301 See Plans and Pricing
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-006 Apr 2, 2012 7,413,747 See Plans and Pricing
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 8,492,416 See Plans and Pricing
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-001 May 9, 2007 6,884,434 See Plans and Pricing
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-002 Nov 30, 1999 4,943,639*PED See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for UCB INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 1000 mg ➤ Subscribe 2011-01-07
➤ Subscribe Tablets 7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg ➤ Subscribe 2004-01-15
➤ Subscribe Extended-release Transdermal Film 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr ➤ Subscribe 2013-11-26
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe 2012-10-29
➤ Subscribe Injection 10 mg/mL, 20 mL ➤ Subscribe 2016-06-30
➤ Subscribe Orally Disintegrating Tablets 0.25 mg, 0.5 mg, 1 mg and 2 mg ➤ Subscribe 2005-12-27
➤ Subscribe Tablets 1000 mg ➤ Subscribe 2007-01-24
➤ Subscribe Tablets 50 mg, 100 mg, 150 mg, and 200 mg ➤ Subscribe 2012-10-29

Supplementary Protection Certificates for Ucb Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0480717 98C0025 Belgium See Plans and Pricing PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
0888289 SPC/GB09/007 United Kingdom See Plans and Pricing PRODUCT NAME: LACOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/08/470/001 20080829; UK EU/1/08/470/002 20080829; UK EU/1/08/470/003 20080829; UK EU/1/08/470/004 20080829; UK EU/1/08/470/005 20080829; UK EU/1/08/470/006 20080829; UK EU/1/08/470/014 20080829; UK EU/1/08/470/015 20080829; UK EU/1/08/470/016 20080829; UK EU/1/08/470/007 20080829; UK EU/1/08/470/008 20080829; UK EU/1/08/470/009 20080829; UK EU/1/08/470/010 20080829; UK EU/1/08/470/012 20080829; UK EU/1/08/470/013 20080829
2391349 C20160006 00188 Estonia See Plans and Pricing PRODUCT NAME: BRIVARATSETAAM;REG NO/DATE: EU/1/15/1073 18.01.2016
1452524 10/2016 Austria See Plans and Pricing PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 (MITTEILUNG) 20160118
1110543 SPC/GB08/005 United Kingdom See Plans and Pricing SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
1452524 530 Finland See Plans and Pricing
1452524 2016/011 Ireland See Plans and Pricing PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160114
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Express Scripts
AstraZeneca
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.